Core Viewpoint - Jiangsu Kangwei Century Biotechnology Co., Ltd. has implemented a "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan to enhance company quality, stabilize the capital market, and support high-quality economic development [2] Group 1: Business Focus and Core Competitiveness - The company focuses on its main business, enhancing customer satisfaction and increasing R&D investment to improve market competitiveness and technological leadership [2] - The company has over ten years of R&D experience in molecular detection core technologies, making it one of the few domestic biotech firms with a complete business layout in this area [2] - The company has expanded its business into the screening and diagnosis of gastrointestinal diseases and respiratory infectious diseases, developing several innovative products and services [2][3] Group 2: Technological Advancements - The company has established a nanopore sequencing platform, which offers advantages such as ultra-long read lengths, compact and flexible equipment, and short sequencing times [3] - The nanopore sequencing technology has significant application potential in research, breeding, and pharmaceuticals [3] Group 3: Financial Performance - The company reported a total profit of -60.63 million yuan, a year-on-year decrease of 4.96%, and a net profit attributable to the parent company of -55.91 million yuan, down 11.70% year-on-year [3] Group 4: Marketing and Sales Strategy - The company has established 11 domestic sales regions and 2 international sales regions, with marketing offices in 12 cities, enhancing product promotion and market coverage [4] - A CRM system has been implemented to strengthen customer relationships and improve customer satisfaction and loyalty [5] Group 5: R&D and Innovation - The company has obtained multiple medical device registrations and patents, with ongoing R&D projects progressing steadily [6] - R&D expenses for the first half of 2025 amounted to 40.81 million yuan, a decrease of 11.32% year-on-year [5] Group 6: Operational Management - The company has improved operational efficiency through refined management practices across sales, R&D, production, and management [10] - Key performance indicators have been established to monitor production, material management, and customer support [12] Group 7: Corporate Governance and Investor Relations - The company emphasizes the importance of corporate governance and internal control systems to protect shareholder rights [13] - A stock incentive plan has been introduced to align the interests of shareholders and employees, involving 182 individuals [14] Group 8: Shareholder Returns - Due to negative net profits, the company does not meet the conditions for profit distribution but plans to use part of the raised funds for share repurchase to enhance investor confidence [15][16]

导读： GordonSanghera辞任ONTCEO，公司启动继任者寻找程序。他领导ONT21年，推动纳米孔测序技术发展，推出MinION等设 备，服务全球超125国，成就显著。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 Ox ford Nanopore Technologies（ONT），即牛津纳米孔技术公司，近期发布消息称，Gordon Sanghera 已通 知董事会，计划辞去首席执行官（CEO）一职并退出董事会。ONT 董事会现已正式启动寻找继任者的工作，旨在带领 公司迈向新的增长与商业化阶段。 Gordon Sanghera 是一位在生物科技领域极具影响力的人物。他与 Hagan Bay ley 和 IP Group 在 2005 年共同 创立了 ONT。在过往的 20 多年间，他始终担任 ONT 的 CEO。到明年底，他担任这一职位就将满 21 年，随后将 正式卸任。在此之前，Sanghera 博士在生物传感器领域已积累了丰富经验，曾参与牛津自旋技术相关研究，关于血 糖基因的市场化研究成果显著。在 Abbott Labor ...